| pubmed-article:1942761 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1942761 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:1942761 | lifeskim:mentions | umls-concept:C0020443 | lld:lifeskim |
| pubmed-article:1942761 | lifeskim:mentions | umls-concept:C0024027 | lld:lifeskim |
| pubmed-article:1942761 | lifeskim:mentions | umls-concept:C0205225 | lld:lifeskim |
| pubmed-article:1942761 | pubmed:issue | 8 | lld:pubmed |
| pubmed-article:1942761 | pubmed:dateCreated | 1991-12-16 | lld:pubmed |
| pubmed-article:1942761 | pubmed:abstractText | The results of 12 weeks treatment of primary hyperlipidemias with Lovastatin are presented. This drug belonging to a new generation of hypercholesterolemic drugs inhibits the endogenous synthesis of cholesterol by means of inhibiting the HMG-CoA reductase. The sample consisted of 30 men aged 28-68 years: in 17 of them heterozygotic familial hypercholesterolemia (FH) was diagnosed and in 13--primary non familial hypercholesterolemia (NFH). After 12 weeks of treatment in both groups a significant reduction of total serum cholesterol concentration was observed--(-28%) and--(-32%) as well as LDL-cholesterol concentration (in both groups about -37%) and apo B concentration--(-32%) and -34%. Only in one patients with NFH a significant reduction of VLDL-cholesterol (-29%) and or triglycerides (-15%) concentrations was observed. In this group also a 9% increase of HLD-cholesterol, mainly HDL-2 concentration, was found. Side effects were observed in 6 patients--in 4 of them a minor increase of ALAT, AsPAT or CPK activities (less than 3 times above norm were observed) without any symptoms and with a spontaneous normalization with no need to stop treatment, and in 2 of them abdominal pains not causing drug treatment cessation. | lld:pubmed |
| pubmed-article:1942761 | pubmed:language | pol | lld:pubmed |
| pubmed-article:1942761 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1942761 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1942761 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1942761 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1942761 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1942761 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1942761 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1942761 | pubmed:issn | 0022-9032 | lld:pubmed |
| pubmed-article:1942761 | pubmed:author | pubmed-author:RywikSS | lld:pubmed |
| pubmed-article:1942761 | pubmed:author | pubmed-author:ChotkowskaEE | lld:pubmed |
| pubmed-article:1942761 | pubmed:author | pubmed-author:BednarekMM | lld:pubmed |
| pubmed-article:1942761 | pubmed:author | pubmed-author:PolakowskaMM | lld:pubmed |
| pubmed-article:1942761 | pubmed:author | pubmed-author:BrodaGG | lld:pubmed |
| pubmed-article:1942761 | pubmed:author | pubmed-author:Kuzmi?skaAA | lld:pubmed |
| pubmed-article:1942761 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1942761 | pubmed:volume | 35 | lld:pubmed |
| pubmed-article:1942761 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1942761 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1942761 | pubmed:pagination | 84-9 | lld:pubmed |
| pubmed-article:1942761 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:1942761 | pubmed:meshHeading | pubmed-meshheading:1942761-... | lld:pubmed |
| pubmed-article:1942761 | pubmed:meshHeading | pubmed-meshheading:1942761-... | lld:pubmed |
| pubmed-article:1942761 | pubmed:meshHeading | pubmed-meshheading:1942761-... | lld:pubmed |
| pubmed-article:1942761 | pubmed:meshHeading | pubmed-meshheading:1942761-... | lld:pubmed |
| pubmed-article:1942761 | pubmed:meshHeading | pubmed-meshheading:1942761-... | lld:pubmed |
| pubmed-article:1942761 | pubmed:meshHeading | pubmed-meshheading:1942761-... | lld:pubmed |
| pubmed-article:1942761 | pubmed:meshHeading | pubmed-meshheading:1942761-... | lld:pubmed |
| pubmed-article:1942761 | pubmed:meshHeading | pubmed-meshheading:1942761-... | lld:pubmed |
| pubmed-article:1942761 | pubmed:meshHeading | pubmed-meshheading:1942761-... | lld:pubmed |
| pubmed-article:1942761 | pubmed:meshHeading | pubmed-meshheading:1942761-... | lld:pubmed |
| pubmed-article:1942761 | pubmed:meshHeading | pubmed-meshheading:1942761-... | lld:pubmed |
| pubmed-article:1942761 | pubmed:year | 1991 | lld:pubmed |
| pubmed-article:1942761 | pubmed:articleTitle | [Lovastatin in the treatment of primary hypercholesterolemia]. | lld:pubmed |
| pubmed-article:1942761 | pubmed:affiliation | Zak?adu Epidemiologii i Prewencji Chorób Ukadu Krazenia, Instytut Kardiologii, Warszawie. | lld:pubmed |
| pubmed-article:1942761 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1942761 | pubmed:publicationType | English Abstract | lld:pubmed |
